Brief: Inozyme Pharma Publishes Data Supporting INZ-701 As A Potential Treatment For ENPP1 Deficiency
29/04/2021 12:53
April 29 (Reuters) - Inozyme Pharma Inc INZY.O :
* INOZYME PHARMA PUBLISHES DATA SUPPORTING INZ-701 AS A
POTENTIAL
TREATMENT FOR ENPP1 DEFICIENCY
* INOZYME PHARMA INC - PRECLINICAL FINDINGS SUPPORT INCREASE
OF
PPI LEVELS AS A PREDICTIVE MARKER OF THERAPEUTIC BENEFIT
Source text for Eikon: ID:nGNXbgQmlg
Further company coverage: INZY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inozyme Pharma
See all newsBrief: Inozyme Pharma postpones 2025 annual meeting of stockholders
U.S. RESEARCH ROUNDUP-Advansix, Cognizant, Inozyme Pharma
U.S. STOCKS ON THE MOVE-Netflix, Acadia Pharma, CoreWeave
U.S. STOCKS ON THE MOVE-Inozyme Pharma, Emerson Electric, Stanley Black & Decker
Inozyme Pharma rises over 175% on $270 million buyout deal with BioMarin